Raymond James Financial Inc. Takes Position in Bio-Rad Laboratories, Inc. (NYSE:BIO)

Raymond James Financial Inc. purchased a new position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) during the 4th quarter, according to its most recent 13F filing with the SEC. The firm purchased 15,581 shares of the medical research company’s stock, valued at approximately $5,119,000.

A number of other large investors have also bought and sold shares of BIO. Metis Global Partners LLC increased its stake in shares of Bio-Rad Laboratories by 4.4% in the fourth quarter. Metis Global Partners LLC now owns 712 shares of the medical research company’s stock worth $234,000 after buying an additional 30 shares during the period. Signaturefd LLC increased its position in shares of Bio-Rad Laboratories by 13.2% in the fourth quarter. Signaturefd LLC now owns 265 shares of the medical research company’s stock valued at $87,000 after acquiring an additional 31 shares during the period. UMB Bank n.a. raised its stake in shares of Bio-Rad Laboratories by 41.6% during the fourth quarter. UMB Bank n.a. now owns 109 shares of the medical research company’s stock valued at $36,000 after acquiring an additional 32 shares during the last quarter. Thrivent Financial for Lutherans boosted its holdings in shares of Bio-Rad Laboratories by 0.7% during the fourth quarter. Thrivent Financial for Lutherans now owns 4,530 shares of the medical research company’s stock worth $1,488,000 after purchasing an additional 32 shares during the period. Finally, Tokio Marine Asset Management Co. Ltd. grew its stake in shares of Bio-Rad Laboratories by 3.9% in the fourth quarter. Tokio Marine Asset Management Co. Ltd. now owns 900 shares of the medical research company’s stock worth $296,000 after purchasing an additional 34 shares during the last quarter. 65.24% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on BIO shares. Royal Bank of Canada reiterated an “outperform” rating and issued a $481.00 price objective on shares of Bio-Rad Laboratories in a report on Tuesday, January 14th. Wells Fargo & Company dropped their price target on Bio-Rad Laboratories from $320.00 to $270.00 and set an “equal weight” rating for the company in a research note on Thursday, April 17th. Finally, StockNews.com cut shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a report on Monday, February 17th. Three equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. According to MarketBeat.com, Bio-Rad Laboratories has an average rating of “Moderate Buy” and an average target price of $380.20.

Bio-Rad Laboratories Trading Down 3.0 %

NYSE BIO opened at $242.22 on Friday. The stock’s 50 day moving average is $251.03 and its 200 day moving average is $308.49. The company has a quick ratio of 4.85, a current ratio of 6.48 and a debt-to-equity ratio of 0.18. The firm has a market capitalization of $6.78 billion, a PE ratio of -3.72 and a beta of 1.12. Bio-Rad Laboratories, Inc. has a twelve month low of $215.38 and a twelve month high of $387.99.

Bio-Rad Laboratories (NYSE:BIO) last issued its quarterly earnings results on Thursday, February 13th. The medical research company reported $2.90 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.86 by $0.04. Bio-Rad Laboratories had a negative net margin of 71.86% and a positive return on equity of 3.90%. Research analysts forecast that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

About Bio-Rad Laboratories

Bio-Rad Laboratories, Inc manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets.